Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
McKesson
Novartis
Deloitte
Harvard Business School
Chinese Patent Office
Fish and Richardson
US Army
Baxter
Citi

Generated: October 21, 2017

DrugPatentWatch Database Preview

HALAVEN Drug Profile

« Back to Dashboard

Which patents cover Halaven, and when can generic versions of Halaven launch?

Halaven is a drug marketed by Eisai Inc and is included in one NDA. There are four patents protecting this drug.

This drug has forty patent family members in twenty-one countries and ten supplementary protection certificates in ten countries.

The generic ingredient in HALAVEN is eribulin mesylate. One supplier is listed for this compound. Additional details are available on the eribulin mesylate profile page.

Summary for Tradename: HALAVEN

US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list7
Clinical Trials: see list36
Drug Prices:see details
DailyMed Link:HALAVEN at DailyMed

Pharmacology for Tradename: HALAVEN

Drug ClassMicrotubule Inhibitor
Physiological EffectMicrotubule Inhibition
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
HALAVEN
eribulin mesylate
SOLUTION;INTRAVENOUS201532-001Nov 15, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Eisai Inc
HALAVEN
eribulin mesylate
SOLUTION;INTRAVENOUS201532-001Nov 15, 2010RXYesYes► Subscribe► Subscribe► Subscribe
Eisai Inc
HALAVEN
eribulin mesylate
SOLUTION;INTRAVENOUS201532-001Nov 15, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
Eisai Inc
HALAVEN
eribulin mesylate
SOLUTION;INTRAVENOUS201532-001Nov 15, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Eisai Inc
HALAVEN
eribulin mesylate
SOLUTION;INTRAVENOUS201532-001Nov 15, 2010RXYesYes► Subscribe► Subscribe► Subscribe
Eisai Inc
HALAVEN
eribulin mesylate
SOLUTION;INTRAVENOUS201532-001Nov 15, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: HALAVEN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,365,759 Intermediate compounds for preparing macrocylcic analogs► Subscribe
8,148,554Methods and compositions for use in treating cancer► Subscribe
6,653,341 Methods and compositions for use in treating cancer► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: HALAVEN

Country Document Number Estimated Expiration
Norway2011026► Subscribe
Australia2003284242► Subscribe
Cyprus1111516► Subscribe
South Korea100798600► Subscribe
Japan2002518384► Subscribe
Germany69943296► Subscribe
South Africa200007159► Subscribe
European Patent Office2277873► Subscribe
World Intellectual Property Organization (WIPO)2007061874► Subscribe
Hong Kong1035534► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: HALAVEN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2011 00022Denmark► Subscribe
854Luxembourg► Subscribe91854, EXPIRES: 20240616
C0038France► SubscribePRODUCT NAME: ERIBULINE, SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER MESYLATE D'ERIBULINE; REGISTRATION NO/DATE: EU/1/11/678/001 20110317
4Finland► Subscribe
00493Netherlands► SubscribePRODUCT NAME: ERIBULIN, ALSMEDE FARMACEUTISCHE ZOUTEN ERVAN, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/11/678/001-002 20110317
C/GB11/039United Kingdom► SubscribePRODUCT NAME: ERIBULIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT.; REGISTERED: UK EU/1/11/678/001 20110317; UK EU/1/11/678/002 20110317
1087960/01Switzerland► SubscribePRODUCT NAME: ERIBULIN; REGISTRATION NO/DATE: SWISSMEDIC 59489 20110513
/2011Austria► SubscribePRODUCT NAME: ERIBULIN UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/11/678/001-002 20110317
90021-4Sweden► SubscribePRODUCT NAME: ERIBULIN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV, I SYNNERHET ERIBULINMESYLAT; REG. NO/DATE: EU/1/11/678/001-002 20110317
C026/2011Ireland► SubscribeSPC026/2011: 20111128, EXPIRES: 20240615
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Harvard Business School
Farmers Insurance
Covington
Dow
Express Scripts
McKinsey
McKesson
Cantor Fitzgerald
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot